Alzamend Neuro
Quarterly Financials
| Values in thousands | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $76 |
Gross Profit | -12 | 63 | ||
EBITDA | -1,037 | -1,345 | -949 | -837 |
EBIT | -1,358 | -962 | -850 | |
Net Income | -1,039 | -1,361 | -974 | -851 |
Net Change In Cash | 0 | 0 | 0 | 76 |
Free Cash Flow | -1,423 | -3,310 | -1,145 | -1,279 |
Cash | 3,358 | 4,093 | 1,193 | 376 |
Basic Shares | 5,517 | 3,531 | 3,889 | 3,439 |
Annual Financials
| Values in thousands | 2024-04-30 | 2023-04-30 | 2022-04-30 | 2021-04-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -50 | -23 | ||
EBITDA | -9,886 | -14,847 | -12,315 | -4,950 |
EBIT | -9,937 | -14,870 | -12,319 | -9,902 |
Net Income | -9,947 | -14,878 | -12,404 | -5,203 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -8,922 | 12,134 | 1,838 | |
Free Cash Flow | -8,417 | -8,923 | -6,720 | -2,712 |
Cash | 376 | 5,140 | 14,063 | 1,929 |
Basic Shares | 3,382 | 3,250 | 2,969 | 2,421 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-01-31 | -$0.19 |
2024-10-31 | -$0.40 |
2024-07-31 | -$1.25 |
2024-04-30 | -$13.35 |
